Make sure to check out Dr. Daniel Vitt, CEO & President of Immunic Therapeutics, as he discusses with Proactive the extended data on the phase 2 EMPhASIS trial of vidofludimus calcium in RRMS, recently published in Neurology® Neuroimmunology & Neuroinflammation. Use the link below to learn more! #IMUX
📽️ Our CEO & President, Dr. Daniel Vitt, discusses with Proactive the extended data from our phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, now published in Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. Tune in! 🧠 ▶️ https://bit.ly/4dmr8De American Academy of Neurology #Immunic #IMUX #Vidofludimus #IMU838 #EMPhASIS #neurofilament #NfL #RRMS #MultipleSclerosis #MS #MSResearch #ClinicalTrials #Neurology #SciencePublication